A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer Patients
M. N. Nguyen, H. Q. Tran, P. L. Luu, V. T. Than, D. Clarke, H. N. Lam, D. T. Nguyen, K. V. T. Le, T. V. Nguyen, M. T. Le, T. X. Hoang, P. Q. Duy, H. T. Tran
The paper identifies an ASMT gene signature that predicts recurrence risk and therapeutic response in breast cancer patients, showing improved outcomes with melatonin and tamoxifen combination therapy.
bioRxiv · Nov 17, 2018Cancer Biology